news
Press releases.
09/16/2024
Velsera Technology Paves the Way for Advanced Cancer Diagnostics with FDA Approval of Illumina TruSight™ Oncology Comprehensive IVD
Velsera is excited to announce that our advanced tumor profiling technology is a key component of the knowledge base that supports the Illumina TruSight™ Oncology (TSO) Comprehensive IVD results report. The knowledge base of TSO Comprehensive integrates Velsera’s cutting-edge tum...
Velsera is excited to announce that our advanced tumor profiling technology is a key component of the knowledge base that supports the Illumina TruSig...
06/28/2024
Genoks and Velsera Forge Strategic Partnership to Revolutionize Cancer Diagnostics in Turkey
Genoks, a leading Turkish genomics healthcare company, and Velsera, a global healthcare technology company offering a universal software platform to connect clinical care with discovery, have announced a collaboration aimed at advancing cancer diagnostics and treatment in Turkey ...
Genoks, a leading Turkish genomics healthcare company, and Velsera, a global healthcare technology company offering a universal software platform to c...
06/27/2024
Genetic Sequence Data Analysis & Reporting Accelerated with Velsera's Release of CGW Plus
Velsera is thrilled to announce the launch of CGW Plus, its reimagined Clinical Genomics Workspace (CGW) platform. This update introduces advanced variant quality and clinical evidence review workflows, designed to simplify and accelerate the analysis and reporting of genetic seq...
Velsera is thrilled to announce the launch of CGW Plus, its reimagined Clinical Genomics Workspace (CGW) platform. This update introduces advanced var...
06/03/2024
Velsera and Sentieon’s Pangenotyper Wins Bio-IT World 2024 Best-of-Show
Velsera and Sentieon are pleased to announce their joint receipt of the Best-of-Show award at Bio-IT World 2024 for their innovative NGS secondary analysis solution, Pangenotyper, which improves upon traditional linear genome reference analysis methods by optimizing both accuracy...
Velsera and Sentieon are pleased to announce their joint receipt of the Best-of-Show award at Bio-IT World 2024 for their innovative NGS secondary ana...
04/04/2024
Velsera and Flywheel Team up to Support Multimodal Imaging Genomics Research
Velsera has joined forces with Flywheel and the Center for Data-Driven Discovery in Biomedicine (D3b) based at Children’s Hospital of Philadelphia, to advance the analysis of large-scale genomics and medical imaging datasets.
Velsera has joined forces with Flywheel and the Center for Data-Driven Discovery in Biomedicine (D3b) based at Children’s Hospital of Philadelphia, to...
03/05/2024
Velsera Announces Appointment of Jamie Littlejohns as New Chief Executive Officer
Velsera, a pioneering entity in the field of computational biology with a focus on advancing precision medicine, is delighted to formally announce the appointment of Jamie Littlejohns as its Chief Executive Officer
Velsera, a pioneering entity in the field of computational biology with a focus on advancing precision medicine, is delighted to formally announce the...
11/15/2023
Faster, smarter clinical interpretation workflows unveiled on CGW platform
New clinical evidence review capabilities in Clinical Genomics Workspace (CGW) platform learn users’ reporting preferences and remember past reporting decisions to drive more rapid report signout
New clinical evidence review capabilities in Clinical Genomics Workspace (CGW) platform learn users’ reporting preferences and remember past reporting...
11/03/2023
Velsera & Solaris Health expand access to genetic testing for urology patients
Solaris affiliates will use Velsera’s leading genetic interpretation and clinical reporting platform to offer inherited cancer testing to help patients understand their risks
Solaris affiliates will use Velsera’s leading genetic interpretation and clinical reporting platform to offer inherited cancer testing to help patient...
11/02/2023
Velsera & NVIDIA make Parabricks available on Seven Bridges platform
Collaboration gives global researchers access to NVIDIA's software suite with GPU-accelerated tools to enable faster, more efficient secondary analysis
Collaboration gives global researchers access to NVIDIA's software suite with GPU-accelerated tools to enable faster, more efficient secondary analysi...
10/04/2023
2023 BioTechX Europe
Velsera to highlight how its Seven Bridges platform delivers flexibility, compatibility and collaboration in support of key initiatives like AI/ML in drug discovery and neoantigen research
Velsera to highlight how its Seven Bridges platform delivers flexibility, compatibility and collaboration in support of key initiatives like AI/ML in ...
06/27/2023
Velsera adds two new board members
Rachel Brake, MD, and Ukonwa Ojo bring diverse pharma R&D and consumer marketing experience to support Summa Equity-owned precision medicine company
Rachel Brake, MD, and Ukonwa Ojo bring diverse pharma R&D and consumer marketing experience to support Summa Equity-owned precision medicine compa...
05/17/2023
2023 Bio-IT World Conference
Velsera to showcase new features of ARIA that enable accelerated discovery and target identification from disparate modalities and data sets -- across public, third party and proprietary sources
Velsera to showcase new features of ARIA that enable accelerated discovery and target identification from disparate modalities and data sets -- across...
05/15/2023
Velsera's Diagnostics & Discovery Summit
This inaugural event in Boston was established to help shape the future of precision medicine, featuring key thought leaders and industry visionaries in multi-omics across clinical diagnostics and R&D
This inaugural event in Boston was established to help shape the future of precision medicine, featuring key thought leaders and industry visionaries ...
02/07/2023
Arima Genomics & Velsera announce partnership
Agreement provides enhanced gene fusion detecting capabilities to clinical labs by integrating Arima's targeted NGS pipelines into Velsera's CGW platform
Agreement provides enhanced gene fusion detecting capabilities to clinical labs by integrating Arima's targeted NGS pipelines into Velsera's CGW platf...
01/12/2023
Velsera launches at JP Morgan Healthcare conference
New company represents Summa Equity's vision to improve global health outcomes and advance precision health through data-driven solutions
New company represents Summa Equity's vision to improve global health outcomes and advance precision health through data-driven solutions
No topic found
01/12/2023
Velsera launches at JP Morgan Healthcare conference
New company represents Summa Equity's vision to improve global health outcomes and advance precision health through data-driven solutions
New company represents Summa Equity's vision to improve global health outcomes and advance precision health through data-driven solutions
02/07/2023
Arima Genomics & Velsera announce partnership
Agreement provides enhanced gene fusion detecting capabilities to clinical labs by integrating Arima's targeted NGS pipelines into Velsera's CGW platform
Agreement provides enhanced gene fusion detecting capabilities to clinical labs by integrating Arima's targeted NGS pipelines into Velsera's CGW platf...
05/15/2023
Velsera's Diagnostics & Discovery Summit
This inaugural event in Boston was established to help shape the future of precision medicine, featuring key thought leaders and industry visionaries in multi-omics across clinical diagnostics and R&D
This inaugural event in Boston was established to help shape the future of precision medicine, featuring key thought leaders and industry visionaries ...
05/17/2023
2023 Bio-IT World Conference
Velsera to showcase new features of ARIA that enable accelerated discovery and target identification from disparate modalities and data sets -- across public, third party and proprietary sources
Velsera to showcase new features of ARIA that enable accelerated discovery and target identification from disparate modalities and data sets -- across...
06/27/2023
Velsera adds two new board members
Rachel Brake, MD, and Ukonwa Ojo bring diverse pharma R&D and consumer marketing experience to support Summa Equity-owned precision medicine company
Rachel Brake, MD, and Ukonwa Ojo bring diverse pharma R&D and consumer marketing experience to support Summa Equity-owned precision medicine compa...
10/04/2023
2023 BioTechX Europe
Velsera to highlight how its Seven Bridges platform delivers flexibility, compatibility and collaboration in support of key initiatives like AI/ML in drug discovery and neoantigen research
Velsera to highlight how its Seven Bridges platform delivers flexibility, compatibility and collaboration in support of key initiatives like AI/ML in ...
11/02/2023
Velsera & NVIDIA make Parabricks available on Seven Bridges platform
Collaboration gives global researchers access to NVIDIA's software suite with GPU-accelerated tools to enable faster, more efficient secondary analysis
Collaboration gives global researchers access to NVIDIA's software suite with GPU-accelerated tools to enable faster, more efficient secondary analysi...
11/03/2023
Velsera & Solaris Health expand access to genetic testing for urology patients
Solaris affiliates will use Velsera’s leading genetic interpretation and clinical reporting platform to offer inherited cancer testing to help patients understand their risks
Solaris affiliates will use Velsera’s leading genetic interpretation and clinical reporting platform to offer inherited cancer testing to help patient...
11/15/2023
Faster, smarter clinical interpretation workflows unveiled on CGW platform
New clinical evidence review capabilities in Clinical Genomics Workspace (CGW) platform learn users’ reporting preferences and remember past reporting decisions to drive more rapid report signout
New clinical evidence review capabilities in Clinical Genomics Workspace (CGW) platform learn users’ reporting preferences and remember past reporting...
03/05/2024
Velsera Announces Appointment of Jamie Littlejohns as New Chief Executive Officer
Velsera, a pioneering entity in the field of computational biology with a focus on advancing precision medicine, is delighted to formally announce the appointment of Jamie Littlejohns as its Chief Executive Officer
Velsera, a pioneering entity in the field of computational biology with a focus on advancing precision medicine, is delighted to formally announce the...
04/04/2024
Velsera and Flywheel Team up to Support Multimodal Imaging Genomics Research
Velsera has joined forces with Flywheel and the Center for Data-Driven Discovery in Biomedicine (D3b) based at Children’s Hospital of Philadelphia, to advance the analysis of large-scale genomics and medical imaging datasets.
Velsera has joined forces with Flywheel and the Center for Data-Driven Discovery in Biomedicine (D3b) based at Children’s Hospital of Philadelphia, to...
06/03/2024
Velsera and Sentieon’s Pangenotyper Wins Bio-IT World 2024 Best-of-Show
Velsera and Sentieon are pleased to announce their joint receipt of the Best-of-Show award at Bio-IT World 2024 for their innovative NGS secondary analysis solution, Pangenotyper, which improves upon traditional linear genome reference analysis methods by optimizing both accuracy...
Velsera and Sentieon are pleased to announce their joint receipt of the Best-of-Show award at Bio-IT World 2024 for their innovative NGS secondary ana...
06/27/2024
Genetic Sequence Data Analysis & Reporting Accelerated with Velsera's Release of CGW Plus
Velsera is thrilled to announce the launch of CGW Plus, its reimagined Clinical Genomics Workspace (CGW) platform. This update introduces advanced variant quality and clinical evidence review workflows, designed to simplify and accelerate the analysis and reporting of genetic seq...
Velsera is thrilled to announce the launch of CGW Plus, its reimagined Clinical Genomics Workspace (CGW) platform. This update introduces advanced var...
06/28/2024
Genoks and Velsera Forge Strategic Partnership to Revolutionize Cancer Diagnostics in Turkey
Genoks, a leading Turkish genomics healthcare company, and Velsera, a global healthcare technology company offering a universal software platform to connect clinical care with discovery, have announced a collaboration aimed at advancing cancer diagnostics and treatment in Turkey ...
Genoks, a leading Turkish genomics healthcare company, and Velsera, a global healthcare technology company offering a universal software platform to c...
09/16/2024
Velsera Technology Paves the Way for Advanced Cancer Diagnostics with FDA Approval of Illumina TruSight™ Oncology Comprehensive IVD
Velsera is excited to announce that our advanced tumor profiling technology is a key component of the knowledge base that supports the Illumina TruSight™ Oncology (TSO) Comprehensive IVD results report. The knowledge base of TSO Comprehensive integrates Velsera’s cutting-edge tum...
Velsera is excited to announce that our advanced tumor profiling technology is a key component of the knowledge base that supports the Illumina TruSig...
No topic found
Media inquiries.
The dedicated team at Velsera is always eager to talk about the exciting ways we are revealing the true promise of precision medicine.
If you are interested in learning more about Velsera and our solutions, or if you have specific questions related to a recent company announcement, please complete our contact form and indicate you are with the media.